Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
11.02
-0.01 (-0.09%)
Feb 21, 2025, 4:00 PM EST - Market closed
Keros Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Keros Therapeutics stock have an average target of 45.33, with a low estimate of 15 and a high estimate of 111. The average target predicts an increase of 311.34% from the current stock price of 11.02.
Analyst Consensus: Buy
* Price targets were last updated on Jan 17, 2025.
Analyst Ratings
The average analyst rating for Keros Therapeutics stock from 11 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 2 | 2 | 2 |
| Buy | 3 | 5 | 5 | 5 | 3 | 3 |
| Hold | 0 | 0 | 0 | 4 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 8 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Jan 21, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $40 → $15 | Buy | Maintains | $40 → $15 | +36.12% | Jan 17, 2025 |
| Wedbush | Wedbush | Buy → Hold Downgrades $47 → $15 | Buy → Hold | Downgrades | $47 → $15 | +36.12% | Jan 17, 2025 |
| Guggenheim | Guggenheim | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jan 17, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $44 → $41 | Buy | Maintains | $44 → $41 | +272.05% | Jan 16, 2025 |
Financial Forecast
Revenue This Year
608.94K
from 151.00K
Increased by 303.27%
Revenue Next Year
61.20K
from 608.94K
Decreased by -89.95%
EPS This Year
-5.29
from -5.20
EPS Next Year
-4.94
from -5.29
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 1.1M | 420,000 | 42.0M | |||
| Avg | 608,940 | 61,200 | 5.4M | |||
| Low | 98,000 | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 600.7% | -31.0% | 68,527.5% | |||
| Avg | 303.3% | -89.9% | 8,674.5% | |||
| Low | -35.1% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -5.00 | -3.36 | -2.36 | |||
| Avg | -5.29 | -4.94 | -4.45 | |||
| Low | -5.39 | -6.42 | -6.81 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.